A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination With Anti-PD-1 Therapy (AB122) in Patients With Advanced Dedifferentiated Liposarcoma
Sponsor: Memorial Sloan Kettering Cancer Center
A PHASE2 clinical study on Dedifferentiated Liposarcoma and Metastatic Dedifferentiated Liposarcoma, this trial is ongoing. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 7 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Feb 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Jul 2023 — Feb 2024 [monthly]
Recruiting PHASE2
First recorded
May 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .